The validation cohort had a lower prevalence of anemia, three-vessel disease, use of intra-aortic balloon pump, use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and use of beta-blockers than the derivation cohort. The gene discussed is ACE; the disease is anemia.